Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, completed a $15m financing round from existing shareholders. The funds will support continued clinical and development activities for V-212 which has shown positive topline data in a Phase 1 trial. V-202 is a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumo-coccal disease caused by Streptococcus pneumoniae (Spn) infections.
VISCHER acts as legal advisor of Virometix with a team of Matthias Staehelin, Pauline Pfirter, Natacha Tang and Francesco Catale (all Corporate/M&A) as well as Nadia Tarolli (Tax).
Author: Matthias Staehelin
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]
Nadia Tarolli Schmidt
Attorney at Law, Swiss Certified Tax Expert
- Partner
- +41 58 211 33 54
- [email protected]